Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018

Seattle Genetics (SGEN) Reports FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy

Seattle Genetics, Inc. (NASDAQ: SGEN) today announced a new approval for ADCETRIS® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S. Food and Drug Administration (FDA) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not... More

BioCryst Pharma (BCRX) Reports Data Highlighting the Rapid & Sustained Plasma Concentrations of BCX7353 in HAE Patients

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual... More

BeiGene (BGNE) Reports Preliminary Clinical Data on PARP Inhibitor Pamiparib

BeiGene, Ltd. (NASDAQ: BGNE) today announced the presentation of preliminary clinical data from an ongoing Phase 1/2 trial of its investigational PARP inhibitor, pamiparib, in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory (R/R) glioblastoma multiforme (GBM). These data are being presented at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held November 15 to 18 in New Orleans, LA. Discovered by BeiGene scientists in Beijing, pamiparib is currently in Phase 3 trials globally and in China as a monotherapy... More

DBV Technologies (DBVT) Announces Daniel Tasse as New CEO

DBV Technologies (NASDAQ: DBVT) today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.

"The Board is very pleased to welcome Daniel, who is a seasoned executive and accomplished leader. He brings a unique blend of operational experience, expertise and passion to DBV, which will be instrumental as... More

Syros Pharmaceuticals (SYRS) Highlights Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism

Syros Pharmaceuticals (NASDAQ: SYRS) today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors. These data, the first clinical data reported on a selective CDK7 inhibitor, were highlighted in an oral plenary session at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Dublin.

These initial data on SY-1365 are highly encouraging, said Dejan Juric, M.D., Director of the Termeer Center for Targeted Therapies at Massachusetts General Hospital... More

Ra Pharmaceuticals (RARX) Reports Election of Bo Cumbo to Board

Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important roles in the successful launch of 11 products across multiple organizations and therapeutic categories, including rare neuromuscular diseases, hepatitis, HIV, and cardiovascular disease.

In his more than twenty-year career in the biotechnology and pharmaceutical sectors, Bo has played an integral role in the planning and implementation of numerous, highly successful and... More